Preetesh Jain, MD, PhD, The University of Texas MD Anderson Cancer Center, Houston, TX, shares the findings of a study that aimed to understand the impact of the tumor microenvironment (TME) of mantle cell lymphoma (MCL) on patient outcomes and the development of resistance to Bruton’s tyrosine kinase inhibitors (BTKi). In this cohort study, biopsies from patients with MCL treated with BTKi were analyzed and it was found that patients with immune cell-depleted TMEs had poorer outcomes and were more likely to develop BTKi resistance. Dr Jain explains the potential use of the TME as a biomarker, which could inform how patients will respond to treatments, including CAR-T therapy. This interview took place at the 17th International Conference on Malignant Lymphoma (ICML), held in Lugano, Switzerland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.